Search research articles
Contact Us
Filters
Showing results (51-60 of 96) with videos related to
Page
of 10
Sort By:
British Journal of Cancer
|
February 21, 2012
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes
B Dutta, L Pusztai, Y Qi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 1, 2008
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
F Peintinger, A U Buzdar, H M Kuerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
C Liedtke, K Broglio, S Moulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
C Mazouni, S-W Kau, D Frye, et al.
ESMO Open
|
February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer
A Grinshpun, D Dustin, M Cai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 28, 2018
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
S J Luen, R Salgado, M V Dieci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
Which threshold for ER positivity? a retrospective study based on 9639 patients
M Yi, L Huo, K B Koenig, et al.
The Oncologist
|
June 15, 2023
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Jennifer K Litton, J Thaddeus Beck, Jason M Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2004
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
M Ayers, W F Symmans, J Stec, et al.
JAMA Oncology
|
January 1, 2016
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy
Sarah S Mougalian, Mike Hernandez, Xiudong Lei, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 96) with videos related to
Sort By:
Page
of 10
British Journal of Cancer
|
February 21, 2012
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes
B Dutta, L Pusztai, Y Qi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 1, 2008
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
F Peintinger, A U Buzdar, H M Kuerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
C Liedtke, K Broglio, S Moulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
C Mazouni, S-W Kau, D Frye, et al.
ESMO Open
|
February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer
A Grinshpun, D Dustin, M Cai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 28, 2018
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
S J Luen, R Salgado, M V Dieci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
Which threshold for ER positivity? a retrospective study based on 9639 patients
M Yi, L Huo, K B Koenig, et al.
The Oncologist
|
June 15, 2023
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Jennifer K Litton, J Thaddeus Beck, Jason M Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2004
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
M Ayers, W F Symmans, J Stec, et al.
JAMA Oncology
|
January 1, 2016
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy
Sarah S Mougalian, Mike Hernandez, Xiudong Lei, et al.
Page
of 10